{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:24:29Z","timestamp":1790792669671,"version":"4.1.0"},"reference-count":59,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T00:00:00Z","timestamp":1512345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ruxolitinib exerts immunosuppressive activity that may increase the risk of infectious complications. We performed a systematic review of the literature with the aim of estimating the risk of infections in patients treated with ruxolitinib. Studies were identified by electronic search of MEDLINE and EMBASE database. Differences in the incidence of infectious events between ruxolitinib and comparison groups were expressed as odds ratios (ORs) and 95% confidence intervals (95% CI). Five phase III randomized clinical trials (RCTs) (3 phase IIIa with their extended phase and 2 phase IIIb), 6 phase IV studies and 28 case reports were included in this systematic review. Ruxolitinib was associated with a statistically significant increased risk of herpes zoster infection compared to control group in 3 RCTs including patients with polycythemia vera (OR 7.39 [1.33, 41.07]) and in a pooled analysis of the extended phase IIIa RCTs (OR 5.20 [95%CI 1.27, 21.18]). In the larger phase IV post\u2010marketing study, the incidence of the most frequent infections was 8% for herpes zoster, 6.1% for bronchitis and 6% for urinary tract infections. In the published case reports, the most frequent infections were tuberculosis (<jats:italic>N<\/jats:italic>\u2009=\u200910), hepatitis B reactivation (<jats:italic>N<\/jats:italic>\u2009=\u20095) and pneumocystis jeroveci infection (<jats:italic>N<\/jats:italic>\u2009=\u20092). Evidence is not solid enough to accurately estimate the risk of infection in ruxolitinib\u2010treated patients. However, published data clearly suggest that the infection risk may be clinically relevant. Well\u2010designed studies are warranted to evaluate the risk of ruxolitinib\u2010associated infection, in order to identify the most appropriate antimicrobial prophylactic strategy.<\/jats:p>","DOI":"10.1002\/ajh.24976","type":"journal-article","created":{"date-parts":[[2017,11,18]],"date-time":"2017-11-18T07:42:45Z","timestamp":1510990965000},"page":"339-347","source":"Crossref","is-referenced-by-count":221,"title":["Ruxolitinib\u2010associated infections: A systematic review and meta\u2010analysis"],"prefix":"10.1002","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6510-8616","authenticated-orcid":false,"given":"Federico","family":"Lussana","sequence":"first","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XIII Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"Medicina III, Ospedale San Paolo, ASST Santi Paolo e Carlo Dipartimento di Scienze della Salute Universit\u00e0 degli Studi di Milano Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XIII Bergamo Italy"},{"name":"Department of Oncology and Hematology Universit\u00e0 degli Studi di Milano Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Squizzato","sequence":"additional","affiliation":[{"name":"Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical and Experimental Medicine University of Insubria Varese Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,12,4]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0417-z"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712461047"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119545"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-531103"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-015-0284-z"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-484642"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3264"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1302135"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14382"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30558-7"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.148"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115840"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143644"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143677"},{"issue":"3","key":"e_1_2_6_25_1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00277-016-2884-7","article-title":"Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph\u2010negative MPN","volume":"96","author":"Breccia M","year":"2017","journal-title":"Ann Hematol."},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1179\/1607845415Y.0000000036"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.08.003"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2130-z"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24572"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2684-0"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.235"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2107.150138"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2532-7"},{"issue":"5","key":"e_1_2_6_34_1","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3109\/10428194.2014.963082","article-title":"Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis","volume":"56","author":"Chen YH","year":"2015","journal-title":"Leuk Lymphoma."},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-5-552"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1302895"},{"issue":"8","key":"e_1_2_6_37_1","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/leu.2014.104","article-title":"Disseminated tuberculosis associated with ruxolitinib","volume":"28","author":"Hopman RK","year":"2014","journal-title":"Leukemia."},{"key":"e_1_2_6_38_1","first-page":"A8650","article-title":"[Fatal tuberculosis during treatment with ruxolitinib]","volume":"159","author":"Keizer S","year":"2015","journal-title":"Ned Tijdschr Geneeskd."},{"key":"e_1_2_6_39_1","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1182\/blood.V122.21.1596.1596","article-title":"Efficacy of ruxolitinib in Korean myelofibrosis patients and cases complicated TB lymphadenitis during the treatment","volume":"122","author":"Kim Y\u2010K","year":"2013","journal-title":"Blood."},{"issue":"10","key":"e_1_2_6_40_1","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2169\/internalmedicine.55.5529","article-title":"Elevation of the Hepatitis B virus DNA during the treatment of polycythemia vera with the JAK kinase inhibitor ruxolitinib","volume":"55","author":"Kirito K","year":"2016","journal-title":"Intern Med."},{"key":"e_1_2_6_41_1","first-page":"164","article-title":"Pneumocystis jirovecii pneumonia associated with Ruxolitinib therapy in a patient with myelofibrosis","volume":"37","author":"Knodler A","year":"2014","journal-title":"Oncology Research and Treatment."},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2748-1"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2718-7"},{"issue":"3","key":"e_1_2_6_44_1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jinf.2012.11.011","article-title":"Ruxolitinib can mask symptoms and signs of necrotizing fasciitis","volume":"66","author":"Landman GW","year":"2013","journal-title":"J Infect."},{"issue":"02","key":"e_1_2_6_45_1","first-page":"bcr2014204950","article-title":"Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy","volume":"2014","author":"Lee SC","year":"2014","journal-title":"BMJ Case Rep."},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2183-0"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12878-015-0029-1"},{"issue":"6","key":"e_1_2_6_48_1","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00277-013-1936-5","article-title":"Hepatitis B virus reactivation associated with ruxolitinib","volume":"93","author":"Shen CH","year":"2014","journal-title":"Ann Hematol."},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.035"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1413918"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-1604"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13404"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24688"},{"key":"e_1_2_6_54_1","first-page":"87","article-title":"Pulmonary cryptococcosis in a ruxolitinib\u2010treated patient with primary myelofibrosis","volume":"22","author":"Hirano A","year":"2017","journal-title":"Respir Med Case Rep."},{"issue":"6","key":"e_1_2_6_55_1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.dld.2017.03.004","article-title":"Occult hepatitis B infection reactivation after ruxolitinib therapy","volume":"49","author":"Perricone G","year":"2017","journal-title":"Dig Liver Dis."},{"key":"e_1_2_6_56_1","first-page":"7304","article-title":"A myelofibrosis case that develops mycobacterial infection after ruxolitinib treatment","volume":"10","author":"Malkan UY","year":"2017","journal-title":"Int J Clin Exp Med."},{"key":"e_1_2_6_57_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial","author":"Harrison CN","year":"2017","journal-title":"Blood."},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.30"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.296"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3198"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24976","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:53:33Z","timestamp":1695574413000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,4]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/ajh.24976"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24976","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,4]]}}}